Opdivo Set To Break $1bn Japan Barrier On Lung Cancer Use

Sales of immuno-oncology drug Opdivo in Japan are surpassing even Ono's raised projections and seem set to head for the stars following major new indications, although potential one-off price cuts are casting a shadow over the expected stellar growth.